On September 16, 2024, Steven Chapman, CEO and President of Natera Inc (NTRA, Financial), executed a sale of 5,024 shares of the company. The transaction was filed on September 18, 2024, as reported in the SEC Filing. Following this transaction, the insider now owns 195,686 shares of Natera Inc.
Natera Inc specializes in genetic testing and diagnostics with a focus on prenatal, oncological, and organ health tests. The company's innovative technologies provide detailed genetic information that supports medical decisions and patient management.
Over the past year, Steven Chapman has sold a total of 259,935 shares and has not purchased any shares. This recent sale is part of a broader trend within Natera Inc, where there have been 100 insider sells and no insider buys over the past year.
Shares of Natera Inc were priced at $128.48 on the day of the sale. The company currently holds a market cap of approximately $15.72 billion. According to the GF Value, the intrinsic value of the stock is estimated at $77.14, indicating that the stock is significantly overvalued with a price-to-GF-Value ratio of 1.67.
The GF Value is determined by historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and estimated future business outcomes.
This insider sale could be of interest to investors tracking insider behaviors, especially in the context of the company's valuation and stock performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
